Literature DB >> 16809153

Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma.

Enrique Castellón1, Marisa Clementi, Catalina Hitschfeld, Catherine Sánchez, Dixan Benítez, Leonardo Sáenz, Héctor Contreras, Christian Huidobro.   

Abstract

Contradictory data have been reported regarding the effect of GnRH agonists and antagonists on cell growth and survival, using prostate cancer-derived cell lines expressing either endogenous or exogenous GnRH receptors. We addressed the issue studying the effect of leuprolide (agonist) and cetrorelix (antagonist) on cell growth, apoptosis and GnRH receptor expression using a primary cell coculture system. Also, binding characteristics of prostate GnRH receptor in this culture system are described. Epithelial and stromal cells were obtained from prostate adenocarcinoma samples and cocultured in a bicameral system. Expression of GnRH receptors was evaluated by semiquantitative RT-PCR (transcript level) and Western blot (protein level). Cell growth was estimated by MTT method and apoptosis by DNA fragmentation using COMET assay. Saturation and competition binding studies were carried out using 125I-GnRH as radioligand. GnRH receptors from cell cultures of prostate cancer exhibited a single class of binding sites with a Kd of 1.11 +/- 0.28 nM and a Bmax of 2.81 +/- 0.37 pmol/mg of membrane protein for GnRH. Leuprolide and cetrorelix showed no effect on GnRH receptor expression. Both analogues showed a significant reduction in cell growth rate and an increase in DNA-fragmented cell number. These effects were dependent on the analogue concentrations (from 5-20 ng/mL). Considering that the culture system used in this work represents more closely the in vivo conditions of tumor cells than metastatic derived cell lines, we conclude that GnRH analogues have a significant inhibitory effect on cell viability of cells expressing GnRH receptors. In addition, GnRH receptors expressed in tumor prostatic cells seem not discriminate between agonist and antagonist, both analogues activating these receptors. Also, leuprolide and cetrorelix treatments did not influence GnRH receptor expression in our culture system. These differences with pituitary receptors may be explained by differences in affinity, transduction mechanism and molecular context in prostatic tissue.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16809153     DOI: 10.1080/07357900600629591

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  14 in total

1.  Knockdown of Hepatic Gonadotropin-Releasing Hormone by Vivo-Morpholino Decreases Liver Fibrosis in Multidrug Resistance Gene 2 Knockout Mice by Down-Regulation of miR-200b.

Authors:  Konstantina Kyritsi; Fanyin Meng; Tianhao Zhou; Nan Wu; Julie Venter; Heather Francis; Lindsey Kennedy; Paolo Onori; Antonio Franchitto; Francesca Bernuzzi; Pietro Invernizzi; Kelly McDaniel; Romina Mancinelli; Domenico Alvaro; Eugenio Gaudio; Gianfranco Alpini; Shannon Glaser
Journal:  Am J Pathol       Date:  2017-05-12       Impact factor: 4.307

2.  An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer.

Authors:  Laurent Boccon-Gibod; Egbert van der Meulen; Bo-Eric Persson
Journal:  Ther Adv Urol       Date:  2011-06

3.  Evaluation of the Biological Properties and the Enzymatic Stability of Glycosylated Luteinizing Hormone-Releasing Hormone Analogs.

Authors:  Shayli Varasteh Moradi; Pegah Varamini; Istvan Toth
Journal:  AAPS J       Date:  2015-05-09       Impact factor: 4.009

Review 4.  The basic biochemistry and molecular events of hormone therapy.

Authors:  Elahe A Mostaghel; Robert B Montgomery; Daniel W Lin
Journal:  Curr Urol Rep       Date:  2007-05       Impact factor: 3.092

5.  GnRH receptor expression in human prostate cancer cells is affected by hormones and growth factors.

Authors:  Cristiana Angelucci; Gina Lama; Fortunata Iacopino; Silvia Ferracuti; Aldo V Bono; Robert P Millar; Gigliola Sica
Journal:  Endocrine       Date:  2009-04-28       Impact factor: 3.633

6.  Abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer.

Authors:  Takashi Ueda; Takumi Shiraishi; Saya Ito; Munehiro Ohashi; Toru Matsugasumi; Yasuhiro Yamada; Atsuko Fujihara; Fumiya Hongo; Koji Okihara; Osamu Ukimura
Journal:  Sci Rep       Date:  2021-05-12       Impact factor: 4.379

Review 7.  Dissecting the Hormonal Signaling Landscape in Castration-Resistant Prostate Cancer.

Authors:  Fabrizio Fontana; Patrizia Limonta
Journal:  Cells       Date:  2021-05-07       Impact factor: 6.600

8.  Leuprorelin acetate long-lasting effects on GnRH receptors of prostate cancer cells: an atomic force microscopy study of agonist/receptor interaction.

Authors:  Gina Lama; Massimiliano Papi; Cristiana Angelucci; Giuseppe Maulucci; Gigliola Sica; Marco De Spirito
Journal:  PLoS One       Date:  2013-01-09       Impact factor: 3.240

Review 9.  Degarelix and its therapeutic potential in the treatment of prostate cancer.

Authors:  Christian Doehn; Martin Sommerauer; Dieter Jocham
Journal:  Clin Interv Aging       Date:  2009-05-14       Impact factor: 4.458

10.  Non-genomic action of resveratrol on androgen and oestrogen receptors in prostate cancer: modulation of the phosphoinositide 3-kinase pathway.

Authors:  D A Benitez; E Pozo-Guisado; M Clementi; E Castellón; P M Fernandez-Salguero
Journal:  Br J Cancer       Date:  2007-05-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.